Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxervate for individualized treatment of diabetic keratopathy
ChiCTR2200058806Phase 4Completed
- Sponsor
- Qingdao Eye Hospital of Shandong First Medical University
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cenegermin in diabetic keratopathy (DK), sponsored by Qingdao Eye Hospital of Shandong First Medical University. Primary endpoints: Slit-lamp examination, Sodium fluorescein staining and 2 more. Started Apr 2022; status: completed.
02
Drugs
cenegermin
03
Conditions
diabetic keratopathy (DK)
Beyond the preview
Go deeper on ChiCTR2200058806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058806.